Cancer Immunotherapy: Industry Updates

The report defines immunotherapy industry as the cancer treatment that uses patient’s own immune system to help fight cancer. This Immunotherapy is the treatment that involves with broad classes of drugs used to help the immune system to fight against the cancer cells. Immunotherapy may work by stopping the cancer cells to grow to the other parts of the body and helping the immune system by destroying the cancer cells. The use of immunotherapy cancer treatment has many advantages for instance in skin cancer treatment, radiation or chemotherapy is not as effective as immunotherapy treatment.

The growing prevalence of cancer across the world is the key factor that drives the growth of the cancer drug industry. According to WHO, Globally, 9.6 million cancer patient deaths were recorded in 2018 and it is a second leading cause of death. The several factors such as the growing ageing population, rapidly changing lifestyles, bacterial infections, eating and drinking habits and others are responsible for the increasing cancer burden worldwide.  

Cancer immunotherapy industry by therapeutic area is segmented as lung cancer, melanoma, breast cancer, colorectal cancer, blood cancer, prostate cancer and others.  Among these types of lung therapeutic area holds maximum shares in the cancer immunotherapy industry. Female breast, and colorectum along with lung cancer are the major types of cancer that are responsible for one-third of the cancer incidence and mortality burden worldwide. In addition, rapidly rising tobacco consumption habits among teenagers is accountable for the rising prevalence of lung cancer.

The cancer immunotherapy industry covers North America, Europe, Asia-Pacific, and Rest of the World geographies in the scope of the report. North America has dominated the cancer immunotherapy industry followed by Europe in 2017. In addition, Asia Pacific is estimated to the fastest growing region in the cancer industry. According to the National Cancer Institute (NCI), 1,735,350 new cases of cancer will be diagnosed in the United States in 2018.

The growing prevalence of cancer, favorable health insurance policies and developed healthcare infrastructure are driving the growth of this industry in the North America Region. Moreover, Asia Pacific is the fastest growing region in cancer immunotherapy industry owing to the growing awareness about cancer treatment drugs, ongoing developments in immunotherapy drugs and a Growing aging population.

The report provides profiles of the companies in the cancer immunotherapy industry such as Glaxosmithkline Plc, F.Hoffmann-La Roche Ltd., Eli Lilly and Company, Pfizer, Inc., Bristol-Myers Squibb Company, AstraZenca Plc, Amgen, Inc., Novartis AG, Merck & Co., Inc., and Others

Read Detailed @ https://bit.ly/2DDJeSj